Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson acquired 6,250 shares of the company’s stock in a transaction on Friday, June 26th. The stock was acquired at an average price of $24.95 per share, for a total transaction of $155,937.50. Following the purchase, the chief financial officer directly owned 33,054 shares of the company’s stock, valued at approximately $824,697.30. This trade represents a 23.32% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Sensei Biotherapeutics Stock Down 7.3%
Shares of FTH traded down $1.80 during mid-day trading on Friday, reaching $22.87. The company’s stock had a trading volume of 145,732 shares, compared to its average volume of 82,691. Sensei Biotherapeutics, Inc. has a 1-year low of $6.32 and a 1-year high of $36.76.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on FTH shares. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a report on Monday. They issued a “buy” rating and a $60.00 price objective on the stock. Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a research report on Friday. They issued an “outperform” rating and a $57.00 price objective on the stock. Finally, Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $58.50.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
